false 0001829247 0001829247 2024-02-09 2024-02-09 0001829247 BFRG:CommonStockParValue0.00001PerShareMember 2024-02-09 2024-02-09 0001829247 BFRG:TradeableWarrantsMember 2024-02-09 2024-02-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 9, 2024

 

BULLFROG AI HOLDINGS, INC.

(Exact name of registrant as specified in charter)

 

Nevada   001-41600   84-4786155
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

325 Ellington Blvd, Unit 317

Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

 

(240) 658-6710

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $ 0.00001 per share   BFRG  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

Tradeable Warrants   BFRGW  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure

 

On February 9, 2024, Bullfrog AI Holdings, Inc. issued a press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number   Description
     
Exhibit 99.1   Press Release dated February 9, 2024.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 9, 2024

 

BULLFROG AI HOLDINGS, INC.  
   
By: /s/ Vininder Singh  
  Vininder Singh  
  Chief Executive Officer  

 

 

 

Exhibit 99.1

 

 

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

 

Gaithersburg, MD – February 9, 2024 – BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD), will participate in a fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15 p.m. ET.

 

The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

 

This collaborative effort marks a pivotal moment in psychiatric research, utilizing over 2,800 brain samples to explore schizophrenia, bipolar disorder, major depressive disorder, and control groups through advanced graph analytics. For the first time, this partnership has enabled the clustering of subjects based on biological data alone, independent of their behavioral diagnoses. This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders. These findings have the potential to not only enhance our understanding of psychiatric conditions but also lay the groundwork for developing more targeted, effective treatments and open the door to prospective revenue-generating partnerships with pharmaceutical companies.

 

To participate in the fireside chat, please register at:

 

https://redchip.zoom.us/webinar/register/WN_gQX4Kwx5RSG0mQyjV80RMw

 

The fireside chat will include a live Q&A session. Questions can also be pre-submitted to rob@redchip.com.

 

About the Lieber Institute for Brain Development (LIBD)

 

The mission of the Lieber Institute for Brain Development and the Maltz Research Laboratories is to translate the understanding of basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. LIBD is an independent, not-for-profit 501(c)(3) organization and a Maryland tax-exempt medical research institute. The Lieber Institute’s brain repository of more than 4,000 human brains is the largest collection of postmortem brains for the study of neuropsychiatric disorders in the world.

 

About BullFrog AI

 

BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

 

For more information visit BullFrog AI at:

 

Website: https://bullfrogai.com

 

LinkedIn: https://www.linkedin.com/company/bullfrogai/

 

 
 

 

 

Safe Harbor Statement

 

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

 

Contact:

 

Investors

 

Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447

 

SOURCE: BullFrog AI Holdings, Inc.

 

 

 

v3.24.0.1
Cover
Feb. 09, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 09, 2024
Entity File Number 001-41600
Entity Registrant Name BULLFROG AI HOLDINGS, INC.
Entity Central Index Key 0001829247
Entity Tax Identification Number 84-4786155
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 325 Ellington Blvd
Entity Address, Address Line Two Unit 317
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code (240)
Local Phone Number 658-6710
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $ 0.00001 per share  
Title of 12(b) Security Common Stock, par value $ 0.00001 per share
Trading Symbol BFRG
Security Exchange Name NASDAQ
Tradeable Warrants  
Title of 12(b) Security Tradeable Warrants
Trading Symbol BFRGW
Security Exchange Name NASDAQ

Bullfrog AI (NASDAQ:BFRG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bullfrog AI Charts.
Bullfrog AI (NASDAQ:BFRG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bullfrog AI Charts.